Swiss Ambassador to Armenia Lukas Gasser: Switzerland will try to contribute to a peaceful settlement of the Nagorno-Karabakh conflict without questioning the established formats such as the OSCE Minsk process
by Nana Martirosyan
A number of drug companies in Armenia have stopped their activities following the adoption of the Good Manufacturing Practice guidelines in Jan 2013, Director of the Organic and Pharmaceutical Chemistry Center of the National Academy of Sciences of Armenia Vigen Topuzyan said on Wednesday.
He said that Armenia has six big drug companies, but none of them have licenses – so, they have either to stop their activities or to continue acting illegally. "Our regulatory authorities refuse to license them as they do not meet the GMP requirements," Topuzyan said.
He noted that in Armenia there is no control over the quality of crude drugs. "This is inadmissible as drugs can be good only if the raw materials they are made of are good," Tomuzyan said.
The Good Manufacturing Practice guidelines were adopted in Armenia in Jan 2013 under a USAID project.